Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed)

https://www.grants.gov/web/grants/view-opportunity.html?oppId=347009
Award Amount
$295,924.00
Maximum Amount
$295,924.00
Assistance Type
Grant
Funding Source
Federal
Implementing Entity
National Institutes of Health
Due Date
Where the Opportunity is Offered
All of California
Eligible Applicant
Business
Additional Eligibility Information
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Contact
NIH Grants Information
Description

This Notice of Funding Opportunity (NOFO) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources, new methods, and approaches that can be applied in testing strategies to help understand the role of environmental chemicals in the etiology of the neurodevelopmental disorders. There is a need for novel and innovative approaches including New Approach Methodologies (NAMs) that can provide effective ways to address current challenges and gaps in the assessment of Developmental Neurotoxicity (DNT). These screening systems or technologies, when fully developed and validated with appropriate throughput and controls, are expected to provide cost-effective, quicker and/or comprehensive results to understand the underlying role of environmental chemicals in the DNT.

Category
Natural Resources

Similar Oppportunities

New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)
SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed)
BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)
Last Updated